

Distinctive Whole-brain Cell-Types Predict Tissue Damage Patterns in Thirteen Neurodegenerative Conditions

Reviewed Preprint

Revised by authors after peer review.

About eLife's process

Reviewed preprint version 2
February 26, 2024 (this version)

Reviewed preprint version 1
September 19, 2023

Posted to preprint server
June 9, 2023

Sent for peer review
May 30, 2023

Veronika Pak, Quadri Adewale, Danilo Bzdok, Mahsa Dadar, Yashar Zeighami, Yasser Iturria-Medina 

Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada • McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada • Ludmer Centre for Neuroinformatics & Mental Health, Montreal, Quebec, Canada • Department of Biomedical Engineering, McGill University, Montreal, Quebec, Canada • School of Computer Science, McGill University, Montreal, Quebec, Canada • Mila – Quebec Artificial Intelligence Institute, Montreal, Quebec, Canada • The Douglas Research Center, Montreal, Quebec, Canada • McGill Centre for Studies in Aging, Montreal Quebec, Canada

 https://en.wikipedia.org/wiki/Open_access

 Copyright information

Abstract

For over a century, brain research narrative has mainly centered on neuron cells. Accordingly, most whole-brain neurodegenerative studies focus on neuronal dysfunction and their selective vulnerability, while we lack comprehensive analyses of other major cell-types' contribution. By unifying spatial gene expression, structural MRI, and cell deconvolution, here we describe how the human brain distribution of canonical cell-types extensively predicts tissue damage in thirteen neurodegenerative conditions, including early- and late-onset Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, amyotrophic lateral sclerosis, mutations in presenilin-1, and three clinical variants of frontotemporal lobar degeneration (behavioural variant, semantic and non-fluent primary progressive aphasia) along with associated 3-repeat and 4-repeat tauopathies and TDP43 proteinopathies types A and C. We reconstructed comprehensive whole-brain reference maps of cellular abundance for six major cell-types and identified characteristic axes of spatial overlapping with atrophy. Our results support the strong mediating role of non-neuronal cells, primarily microglia and astrocytes, in spatial vulnerability to tissue loss in neurodegeneration, with distinct and shared across-disorders pathomechanisms. These observations provide critical insights into the multicellular pathophysiology underlying spatiotemporal advance in neurodegeneration. Notably, they also emphasize the need to exceed the current neuro-centric view of brain diseases, supporting the imperative for cell-specific therapeutic targets in neurodegeneration.

eLife assessment

Pak et al. examined the relationship between the most common spatial patterns of neurodegeneration and transcriptional markers of the density of different cell types in the cerebral cortex. This **valuable** study uses innovative methods to provide **convincing** evidence that patterns of grey matter loss in various forms of dementia are correlated with the anatomical distribution of non-neuronal cell types.

Introduction

Neurodegenerative diseases (NDs) are characterised by substantial neuronal loss in the central and peripheral nervous system¹. In dementia-related conditions like Alzheimer's disease (AD), frontotemporal dementia (FTD), and dementia with Lewy bodies (DLB), neurodegeneration can lead to progressive damage in brain regions related with memory, behaviour, and cognition². Other NDs are thought to primarily affect the locomotor system, including motor neurons in amyotrophic lateral sclerosis (ALS) and nigrostriatal dopaminergic circuitry in Parkinson's disease (PD)³. Although each disorder has its own distinct etiology, progression, affected brain areas, and clinical manifestations, transcriptomics analyses support that most of them share molecular and cellular mechanisms^{4–7}.

While research has been mainly focused on neuronal dysfunction, other brain cells such as astrocytes, microglia, oligodendrocytes, cells of the vascular and peripheral immune systems and their contribution to the disease pathology are gaining more recognition^{8–10}. Depending on the disease stage, non-neuronal cells in the brain can play a dual role, both protective and detrimental, by producing neuroprotective and pro-inflammatory factors. Thus, their complex response can have both positive and negative effects on neuronal health and survival. For example, the activation of glial cells can lead to metabolic stress, disruption of the blood-brain barrier, and reduced energy, all of which contribute to increased neuronal death^{11–15}. In AD, for example, overproduction of pro-inflammatory cytokines leads to the accumulation of amyloid- β and tau plaques, which are known as the major hallmarks of the disease^{12, 16, 17}. This process depends on the innate immune system, which includes microglia and astrocytes^{18, 19}. Peripheral interference from systemic inflammation or the gut microbiome can also alter the progression of neuronal loss²⁰. Growing evidence suggests that these immune-mediated events is a driving force behind the wide range of NDs^{18, 19, 21, 22}. Yet, the exact bases behind how these processes contribute to selective neuronal loss across brain regions remain unclear.

Recent studies have suggested that brain spatial patterns in gene expression are associated with regional vulnerability to some neurodegenerative disorders and their corresponding tissue atrophy distributions^{23–26}. Comparison of transcriptomic patterns in middle temporal gyrus across various brain diseases showed cell-type expression signature unique for neurodegenerative diseases⁷. Although single-cell transcriptomics and proteomics analyses have advanced our knowledge of cell-type compositions associated with pathology in neurodegeneration^{27–29}, these are invariably restricted to a few isolated brain regions, usually needing to be preselected at hand for each specific disease. Due to the invasive nature of tissue acquisition/mapping and further technical limitations for covering extended areas³⁰, no whole-brain maps for the abundance of cell populations in humans are currently available, constraining the analysis of large-scale cellular vulnerabilities in neurological diseases. Accordingly, how spatial cell-types distributions relate to stereotypic regional damages in neurodegeneration remain largely unclear³¹.

Here, we extend previous analysis of cellular-based spatiotemporal vulnerability in neurodegeneration in three fundamental ways. First, we use transcriptomics, structural magnetic resonance imaging (MRI), and advanced cell deconvolution to construct whole-brain reference maps of cellular abundance in healthy humans for six canonical cell-types: neurons, astrocytes, oligodendrocytes, microglia, endothelial cells, and oligodendrocyte precursors. Second, we describe the spatial associations of each healthy level of reference canonical cell-types with atrophy maps from thirteen low-to-high prevalent neurodegenerative conditions, including early- and late-AD, genetic mutations in presenilin-1 (PS1 or PSEN1), DLB, ALS, PD, and both clinical and pathological subtypes of frontotemporal lobar degeneration (FTLD). Third, we identify distinctive cell-cell and disorder-disorder axes of spatial susceptibility in neurodegeneration, obtaining new insights about across-disorders (dis)similarities in underlying pathological cellular systems. We confirm that non-neuronal cells express substantial vulnerability to tissue loss and spatial brain alterations in most studied neurodegenerative conditions, with distinct and shared across-cells and across-disorders mechanisms. This study aids in unraveling the commonalities across a myriad of dissimilar neurological conditions, while also revealing cell-type specific patterns conferring increased vulnerability or resilience to each examined disorder. For further translation and validation of our findings, all resulting analytic tools and cells abundance maps are shared with the scientific and clinical community.

Results

Multimodal data origin and unification approach

We obtained whole-brain voxel-wise atrophy maps for thirteen neurodegenerative conditions, including early- and late-onset Alzheimer's disease (EOAD and LOAD, respectively), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB), mutations in presenilin-1 (PS-1), clinical variants of frontotemporal dementia (the behavioural variant bvFTD and the non-fluent and semantic variants of primary progressive aphasia nfvPPA and svPPA), and FTLD-related pathologies such as FLTD-TDP (TAR DNA-binding protein) types A and C, 3-repeat tauopathy, and 4-repeat tauopathy (see *Materials and Methods, Disease-specific atrophy maps* subsection)^{32–35}. We use the term FTD when addressing the clinical syndromes, and the term FTLD is employed when referencing the histologically confirmed neurodegenerative pathologies³⁶. Pathological diagnosis confirmation was performed for early- and late onset AD, DLB, PS-1, FTLD-TDP types A and C, 3-repeat tauopathy, and 4-repeat tauopathy³², while PD, ALS, and variants of FTD were diagnosed based on clinical and/or neuroimaging criteria^{37–39}, with some ALS patients being histologically confirmed *post-mortem*³⁸. Changes in tissue density in the atrophy maps were previously measured by voxel- and deformation-based morphometry (VBM and DBM; *Materials and Methods, Disease-specific atrophy maps* subsection) applied to structural T1-weighted MR images, and expressed as a t-score per voxel (relatively low negative values indicate greater GM tissue loss/atrophy; ^{40, 41}). All maps are registered to the Montreal Neurological Institute (MNI) brain space⁴². In addition, we obtained bulk transcriptomic data for the adult healthy human brains from the Allen Human Brain Atlas (AHBA)⁴³. This included high-resolution coverage of nearly the entire brain, measuring expression levels for over 20,000 genes from 3702 distinct tissue samples of six post-mortem specimens, and detailed structural MRI data (see *Materials and Methods, Mapping gene expression data*)⁴³.

Using previously validated approaches to infer gene expression levels (in AHBA data) at not-sampled brain locations with Gaussian process regression⁴⁴, mRNA expression levels were completed for all grey matter (GM) voxels in the standardized MNI brain space⁴². Gaussian process regression allows predicting gene expression values for unobserved regions based on the mRNA values of proximal regions. Next, at each GM location, densities for multiple canonical cell-types were estimated using the Brain Cell-type Specific Gene Expression Analysis software (BRETIGEA)⁴⁵. This deconvolution method⁴⁵ accurately estimates cell proportions from bulk

mRNA for six major cell-types (**Fig. 1C**): neurons, astrocytes, oligodendrocytes, microglia, endothelial cells, and oligodendrocyte precursor cells (OPCs). Overall, atrophy levels for thirteen neurodegenerative conditions and proportion values for six major cell-types from healthy brains were unified at matched and standardized locations (MNI space), covering the entire grey matter of the brain (see **Fig. 1** for schematic description).

We hypothesized (and tested in next subsections) that brain tissue damages in neurodegenerative conditions are associated with distinctive patterns of cells distributions, with alterations on major cell-types playing a key role on the development of each disorder and representing a direct factor contributing to brain dysfunction.

Uncovering spatial associations between cell-type abundances and tissue damage in neurodegeneration

First, we investigated whether stereotypic brain atrophy patterns in neurodegenerative conditions show systematic associations with the spatial distribution of canonical cell-type populations in healthy brains. For each condition and cell-type pair, the non-linear Spearman's correlation was calculated with paired atrophy-cell proportion values across 118 cortical and subcortical regions defined by the automated anatomical labelling (AAL) atlas (**Table S1**; ⁴⁶). The results (**Figs. 2A-M**) show clear associations for all the studied conditions, suggesting extensive cell-types related tissue damage vulnerability in NDs. We confirmed that the observed relationships are independent of brain parcellation, obtaining equivalent results for a different brain parcellation (i.e., DKT atlas ⁴⁷; see **Fig. S1**).

As shown in **Figs. 2A-M** and 3A, astrocytes and microglia cell occurrences presented the strongest spatial associations with atrophy in most neurodegenerative conditions, particularly for EOAD, LOAD, DLB, PS1, FTL-3RTau, FTL-4Rtau, FTL-TDP type A, FTL-TDP type C, bvFTD, nfvPPA, and svPPA (all $p < 0.001$). Astrocytes are involved in neuronal support, extracellular homeostasis, and inflammatory regulation in response to injury, and show high susceptibility to senescence and oxidative damage^{48, 49}. Astrocytes also play an important role in the maintenance of the blood-brain barrier (BBB)⁵⁰. There is evidence of endothelium degeneration and vascular dysfunction in AD and PD^{51, 52}. This degeneration may lead to disruption of the BBB, which would allow harmful substances to enter the brain, including inflammatory molecules and toxic aggregated proteins^{52, 53}. Furthermore, the endothelium plays a key role in delivering oxygen and nutrients. The disruption of this process in neurodegeneration may lead to impaired brain function and cognitive decline^{14, 54}.

Similarly involved in neuronal support, microglial cells are the resident macrophages of the central nervous system and key players in the pathology of neurodegenerative conditions including AD, PD, FTD and ALS^{12, 55, 56}. Besides its many critical specializations, microglial activation involvement in prolonged neuroinflammation is of particular relevance in NDs^{11, 57}. At earlier stages of AD, increased population of microglia and astrocytes (microgliosis and astrogliosis) have been observed in diseased regions, due to sustained cellular proliferation in response to disturbances, loss of homeostasis or the accumulation of $A\beta$ ^{13, 58, 59}. Excessive proliferation leads to the transition of homeostatic microglia to its senescent or disease-associated type, also called DAM, via the processes mediated by *TREM2-APOE* signalling^{58, 60, 61}. Increased number of dystrophic microglia, a form of cellular senescence characterized as beading and fragmentation of the branches of microglia, has been seen in multiple NDs such as AD, DLB and TDP-43 encephalopathy⁶². The presence of senescent microglia is believed to ultimately contribute to the failure of brain homeostasis and to clinical symptomatology^{61, 63, 64}.




Figure 1

| Schematic approach for whole-brain cells proportions vulnerability analysis in neurodegeneration. **(A)** Gene expression levels in the AHBA were derived from 3072 distinct tissue samples of six post-mortem healthy human brains. Microarray gene expression data were inferred for each unsampled grey matter voxel using Gaussian process regression. and together with AHBA data were mapped into volumetric MNI space, resulting in the brain-wide transcriptional atlas. Deconvolution algorithm for bulk RNA expression levels was applied to the transcriptional atlas with using well-known cell-type-specific gene markers. Comprehensive volumetric maps showing reconstructed distributions of six canonical cell-types across all grey matter voxels in the brain were created (see *Materials and Methods, Cell-type proportion estimation* subsection). **(B)** Voxel-wise cortical surface visualization (lateral, dorsal, and ventral views) of cell abundance maps for neurons, astrocytes, microglia, endothelial cells, oligodendrocytes, and OPCs. At each voxel, red and blue colors indicate high and low proportion densities, respectively. **(C)** Associations between cell-types proportions from each density map and atrophy values in thirteen neurodegenerative conditions were analysed in 118 grey matter regions predefined by the AAL atlas. Created with BioRender.com




Figure 2

| Spatial associations between tissue integrity and cell-types proportions for thirteen neurodegenerative conditions illustrated in the scatterplots and surface maps (left hemisphere; lateral view) of regional measures. A-M) Strongest Spearman's correlations for EOAD, LOAD, DLB, PS1, FTLD-3Rtau, FTLD-4Rtau, FTLD-TDP43A, FTLD-TDP43C, PD, ALS, bvFTD, nfvPPA, and svPPA, respectively. Atrophy and cell-type density measures were averaged across 118 grey matter regions and projected to the cortical surface of the *fsaverage* template. Each dot in the scatterplots represents a GM region from the AAL atlas (Table S1; see Fig. S1 for equivalent results for the DKT parcellation). Lower tissue integrity score in the scatterplots indicates greater GM loss/atrophy. For a better visual comparison of patterns in atrophy and cell abundance, the atrophy scale was reversed, with higher t-statistic values indicating greater atrophy in the surface plots. Thus, the first color bar ranging from 0 is universal for all cell maps and pathologically confirmed dementia conditions (A-H). Second color bar captures the tissue enlargement in PD, ALS, and variants of FTD (I-M). Notice how astrocyte density significantly correlates with increase in tissue loss in EOAD, DLB, PS1, FTLD-TDP43C, and nfvPPA (A, C, D, H, L; $p < 0.001$). Tissue loss was also associated with increase in microglial proportion in LOAD, FTLD-3Rtau, FTLD-4Rtau, FTLD-TDP43A, bvFTD, and svPPA (B, E, F, G, K, M; $p < 0.001$), and increase in oligodendrocytes in PD (I; $p < 0.001$). Increase in neuronal proportion showed association with decrease in atrophy and tissue enrichment in ALS (J; $p < 0.001$).

Other non-neuronal cells such as oligodendrocytes and endothelial cells also associated with spatial tissue vulnerability to all NDs aside ALS (**Fig. 3A**). Oligodendrocytes are responsible for the synthesis and maintenance of myelin in the brain⁶⁵. Demyelination produces loss of axonal insulation leading to neuronal dysfunctions^{65, 66}. Oligodendrocytes were shown to be highly genetically associated with PD^{67–69} and be particularly vulnerable to the alpha-synuclein accumulation^{70, 71}. In addition, densities of OPCs showed strong correlations with the atrophy patterns of DLB, EOAD, PS1, and FTLD-TDP43 type C. OPCs regulate neural activity and harbor immune-related and vascular-related functions⁷². In response to oligodendrocyte damage, OPCs initiate their proliferation and differentiation for the purpose of repairing damaged myelin⁷³. In AD, PD and ALS, the OPCs become unable to differentiate and their numbers decrease, leading to a reduction in myelin production and subsequent neural damage^{74, 75}.

We observed (**Fig. 3A**) that neuronal abundance distribution is also associated with tissue damage in many neurodegenerative conditions. However, these associations are less strong than for other cell-types, except for the ALS case (**Fig. 2J**). For this disorder, neuron proportions positively correlated with tissue integrity (i.e., the higher the neuronal proportion the less atrophy in a region). This observation suggests that increased neuronal presence at brain regions (relative to all considered cell-types) may have a protective effect in ALS, making neuronal enriched regions less vulnerable to damage in this disorder. In addition, we observed particularly weak associations between neuronal proportions and tissue damage in all three clinical variants of FTD (bvFTD, nvPPA, svPPA) and PD (**Fig. 3A**), suggesting that these conditions may be primarily associated with supportive cell-types (microglia, astrocytes, and oligodendrocytes, respectively; **Figs. 2I**, K-M).

Spatial cell-types grouping exposes distinctive disease-disease mechanisms

Next, we hypothesized that disorders sharing similar biological mechanisms and clinical manifestations present common across-brain patterns of cell-types density associations. **Figure 3A** shows a hierarchical taxonomy dendrogram grouping cell-types and conditions according to their common brain-wide correlation patterns.

The clustergram analysis revealed distinct grouping patterns among various neurodegenerative conditions. All histologically confirmed dementia conditions formed a separate cluster. Notably, EOAD and mutations in PS1, a prevalent cause of familial early-onset AD⁷⁶, grouped together. Interestingly, three clinical subtypes of FTD (bvFTD, nvPPA, and svPPA) displayed similar patterns of cell-type vulnerabilities and diverged into a discrete cluster with PD, separately from ALS and other dementia conditions. However, FTLD-associated pathologies such as TDP-43 proteinopathies (types A and C), as well as 3-repeat and 4-repeat tauopathies, showed patterns more similar to those found in DLB and AD-related conditions (EOAD, LOAD, PS-1) rather than clinical FTD subtypes from a different dataset. This convergence could be attributed to variations in the source dataset; the atrophy maps were derived from different studies and were measured by different techniques, which may have introduced discrepancies in results due to different data acquisition tools and protocols (see Methods).

Patterns in cellular vulnerability in DLB did not strongly resemble PD without dementia (**Fig. 3C**), although both conditions involve alpha-synuclein aggregates⁷⁷. Similar observation can be made for ALS and FTLD. Despite the common presence of TDP-43 abnormal accumulations and their strong genetical overlap⁷⁸, ALS did not group together with FTD variants and FTLD-associated pathologies (FTLD-TDP type A, FTLD-TDP type C) based on patterns of cellular vulnerabilities. All these conditions are known to be pathologically linked, often arising from either tau or TDP-43 accumulation; for instance, TDP-43 is the usual cause of svPPA and approximately half of bvFTD cases, while the other half of bvFTD patients and many nvPPA cases




Figure 3

| Cells and disorders similarities based on shared distributions. A) Dendrogram and unsupervised hierarchical clustering heatmap of Spearman's correlations between cell-type proportions and atrophy patterns of the thirteen neurodegenerative conditions. B) Cell-cell associations based on regional vulnerabilities to tissue loss across neurodegenerative conditions. C) Disorder-disorder similarities across cell-types. In A), red color corresponds to strong positive correlations between cells and disorders, white to no correlation, and dark blue to strong negative correlations.

are associated with tau pathology⁷⁹. These results emphasize the fundamental role of network topology and other factors beyond the presence of toxic misfolded proteins in developing characteristic tissue loss and cellular vulnerability in NDS³⁴, ⁸⁰–⁸².

Among all cell-types, neurons and OPCs spatial density distributions were least associated with tissue atrophy in all thirteen conditions, subsequently clustering together. Astrocytes and microglia distributions similarly showed the strongest associations with all neurodegenerative conditions (**Figure 3B**), and thus formed a separate cluster while still being related with oligodendrocytes and endothelial cells.

Discussion

Previous efforts to describe the composition of the brain's different cell populations related to neurodegeneration have been limited to a few isolated regions. In the most systematic study of its kind, here we characterized large-scale spatial associations between canonical cell-types and brain tissue loss across all cortical and subcortical grey matter areas in thirteen neurodegenerative conditions (including early- and late-AD, PD, DLB, ALS, mutations in PS1, and clinical (bvFTD, nfvPPA, svPPA) and pathological (3-repeat and 4-repeat tauopathies and TDPP43 types A and C) subtypes of FTLT. Starting from healthy brain levels of gene expression and structural MRIs from the Allen Human Brain Atlas⁴³, and extending our analysis with advanced RNAseq-validated cells deconvolution approaches and whole-brain atrophy maps from clinically and/or neuropathologically confirmed disorders, we determined that (i) the spatial distributions of non-neuronal cell-types, primarily microglia and astrocytes, are strongly associated with the spread tissue damage present in many neurodegenerative conditions; (ii) cells and disorders define major axes that underlie spatial vulnerability according with shared cellular mechanisms, which aid in comprehending heterogeneity behind distinct and similar clinical manifestations/definitions; (iii) the generated whole-brain maps of cellular abundance can be similarly used for studying how cellular processes deviate from healthy reference cellular levels in other neurological conditions (e.g., neurodevelopmental and neuropsychiatric disorders). Overall, our findings stress the critical need to surpass the current neuro-centric view of brain diseases and the imperative for identifying cell-specific therapeutic targets in neurodegeneration⁶³. For further translation and validation, all resulting cells abundance maps and analytic tools are freely shared with the community.

We derived, first to our knowledge, high resolution maps of cellular abundance/proportion in the adult human healthy brain for six canonical cell-types, including astrocytes, neurons, oligodendrocytes, microglia, and endothelial cells. As mentioned, previous cellular analyses of neurological conditions have been restricted to expert-selected isolated brain areas. The invasive nature of expression assays, requiring direct access to neural tissue, and other numerous scaling limitations have impeded extensive spatial analyses⁸³. Earlier studies, also using AHBA data, have shown that spatial patterns in gene expression and cell-type-specific genetic markers are associated with both regional vulnerability to neurodegeneration and patterns of atrophy across the brain⁷, ²³–²⁶. Since many neurodegeneration-related genes have similar levels of expression in both affected and unaffected brain areas⁸⁴, characterizing changes in tissue loss associated with reference cell-type proportions in health may provide a clearer perspective on large-scale spatial patterns of cellular vulnerability. Our maps of cells-abundance are available for the scientific and clinical community, potentially allowing researchers to further study spatial variations in cell-types density with macroscale phenotypes. These maps can be used in future studies concerning brain structure and function in both health and disease. They can be also explored in context of other neurological diseases including neurodevelopmental and psychiatric conditions.

Our results demonstrate that all canonical cell-types express vulnerability to dementia-related atrophy of brain tissue, suggesting the disruption of the molecular pathways involving specific cell-types can contribute to their observed dysfunctions and subsequent clinical symptomatology⁶³. Previously, transcriptional profiling of prefrontal cortex in AD showed reduced proportions of neurons, astrocytes, oligodendrocytes, and homeostatic microglia⁸⁵. In contrast, bulk-RNA analysis of diseased AD tissues from various human brain regions observed neuronal loss and increased cell abundance of microglia, astrocytes, and oligodendrocytes^{86, 87}. Furthermore, increased microglial, endothelial cells, and oligodendrocytes population was observed in PD and other Lewy diseases^{68, 88}. Cortical regions exhibiting the most severe atrophy in symptomatic *C9orf72*, *GRN* and *MAPT* mutation carriers with FTD showed increased gene expression of astrocytes and endothelial cells²⁶. Cortical thinning has been demonstrated to correlate with higher proportions of astrocytes, microglia, oligodendrocytes, oligodendrocyte precursor cells, and endothelial cells in cases of AD compared to controls⁸⁹. In line with these results, we observed that regions with increased cell-type proportions, particularly for astrocytes and microglia, are more vulnerable to tissue atrophy in almost all neurodegenerative conditions. This may partly explain the reported cellular proliferation through microglial activation in diseased regions in response to the misfolded protein accumulation or other pathobiological processes^{58, 64}. As disease progresses, the release of inflammatory agents by sustained microglial activation is believed to be responsible for exacerbating neurodegeneration and clinical symptoms^{18, 21}. Microglial activation in pair with grey matter atrophy in frontal cortex were shown to be directly associated with cognitive decline in FTD⁵⁶.

In addition, astrocytes and microglia showed similar strong patterns of associations with all neurodegenerative conditions. Astrocytes and microglia are known to be intimately related in the pathophysiological processes of NDs¹³. Both are key regulators of inflammatory responses in the central nervous system, and given their role in clearing misfolded proteins, dysfunctions of each of them can result in the accumulation of A β and tau^{13, 17}. During the progression of AD and PD, microglia's activation results in an increased capacity to convert resting astrocytes to reactive astrocytes⁹⁰. Recent studies demonstrated that blocking the microglial-mediated conversion of astrocytes to a neurotoxic reactive phenotype could limit neurodegeneration in AD and PD^{90, 91}. Future work should prioritize the exploration of glial and neuron-glia cell-cell interactions, as well as the investigation of the associations between their spatial distributions and the most vulnerable regions. This will advance our understanding of multicellular pathophysiology in neurodegenerative diseases.

Our study also has a number of limitations. Firstly, our analyses were focused on stereotypic atrophy patterns for each disorder. It is known that NDs are highly heterogenous, with molecular, phenotypic, and clinical subtypes potentially varying in atrophy patterns^{92, 93}. Further investigation of cell-type signatures across various subtypes not covered in this study and disease stages may better characterize each case. Additionally, comparing our findings with neuropathological assessments of diseased brain tissues in available regions would be beneficial. While the diagnosis of most dementia conditions used in this study has been histologically confirmed, the diagnosis for clinical variants of FTD, ALS, and PD patients was based on clinical and neuroimaging assessments. In addition, it has been observed that cell-type-related transcriptional changes are different between sexes⁷², making future sex-specific analyses indispensable for further understanding of sex-related pathomechanisms. Examined atrophy maps were coming from different studies (**Table S2**), with differences in data acquisition protocols (e.g., spatial resolution) and technical procedures (e.g., smoothing level, statistical methods). In complementary analyses, we observed almost identical results after smoothing all disorder-specific images with the same kernel size, while they were already mapped at the same spatial resolution for this study and statistically adjusted by acquisition parameters (e.g., field strength) in original studies. Cell-types deconvolution approaches are varied and limited in their precision⁹⁴. Here, we used a previously validated deconvolution method designed for efficiently estimating cell proportions for six major cell-types from bulk mRNA expression⁴⁵. Conveniently,

this method is freely available for researchers (R package, BRETIGEA), which will facilitate reproducibility analyses of our study. Other important considerations are the dynamic nature of gene expression as disease progresses⁹⁵, ⁹⁶, *post-mortem* RNA degradation of the used templates⁹⁷, and the subsequent limited ability of bulk RNA sequencing to reflect cell-to-cell variability, which is relevant for understanding cell heterogeneity and the roles of specific cell populations in disease⁹⁸. Lastly, a promising future direction would be to validate our findings with single-cell spatial analyses.

Materials and Methods

Disorder-specific atrophy maps

Voxel-wise brain atrophy maps in early- and late-onset Alzheimer's disease (EAD and LOAD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB), mutations carriers in presenilin-1, clinical variants of frontotemporal dementia (FTD), and frontotemporal lobar degeneration (FTLD) pathologies (FTLD-TDP types A and C, 3-repeat tauopathy, and 4-repeat tauopathy) were adopted from open data repositories and/or requested from collaborators³²–³⁵, as specified below. Reduction in grey matter (GM) density in diseased atrophy maps relative to controls was measured by voxel- and deformation-based morphometry (VBM and DBM) applied to structural T1-weighted MR images, and thus were expressed as t-score per voxel (relatively low negative t-scores indicate greater GM tissue loss/atrophy)⁴⁰, ⁴¹. VBM is a hypothesis-free technique for analyzing neuroimaging data that characterizes regional tissue concentration differences across the whole brain, without the need to predefine regions of interest⁹⁹. DBM is a similar widely used technique to identify structural changes in the brain across participants, which in addition considers anatomical differences such as shape and size of brain structures¹⁰⁰. See **Table S2** for study-origin, sample size and imaging technique corresponding to each atrophy map.

MRI data for neuropathological dementias were collected from 186 individuals with a clinical diagnosis of dementia and histopathological (post-mortem or biopsy) confirmation of underlying pathology, along with 73 healthy controls³². Data were averaged across participants per condition: 107 had a primary AD diagnosis (68 early-onset (<65 years at disease onset), 29 late onset (≥65 years at disease onset), 10 presenilin-1 mutation carriers), 25 with DLB, 11 with 3-repeat-tauopathy, 17 with 4-repeat-tauopathy, 12 FTLD-TDP type A, and 14 FTLD-TDP type C)³². Imaging data were collected from multiple centres on scanners from three different manufacturers (Philips, GE, Siemens), using a variety of different imaging protocols³². Magnetic field strength varied between 1.0 T (n=15 scans), 1.5 T (n=201 scans) and 3 T (n=43 scans)³². Pathological examination of brain tissue was conducted between 1997 and 2015 according to the standard histopathological processes and criteria in use at the time of assessment at one of four centres: the Queen Square Brain Bank, London; Kings College Hospital, London; VU Medical Centre, Amsterdam and Institute for Ageing and Health, Newcastle³². Atrophy maps were statistically adjusted for age, sex, total intracranial volume, and MRI strength field and site³². Ethical approval for this retrospective study was obtained from the National Research Ethics Service Committee London-Southeast³².

MRI data for PD, consisted of 3T high-resolution T1-weighted scans, were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (www.ppmiinfo.org/data)³⁷. The PPMI is a multi-center international study with approved protocols by the local institutional review boards at all 24 sites across the US, Europe, and Australia³⁷. MRI data were acquired in 16 centers participating in the PPMI project, using scanners from three different manufacturers (GE medical systems, Siemens, and Philips medical systems). The acquisition parameters are detailed in the data set Website: <http://www.ppmiinfo.org/wp-content/uploads/2015/03/PPMI-MRI-Operations-Manual-V7-0-20JAN2015-FINAL.pdf>. 3T high-resolution T1-weighted MRI scans from the

initial visit and clinical data used in constructing atrophy maps were collected from 232 participants with PD and 118 age-matched controls³⁴. PD subjects (77 females; age 61.2 ± 9.1) were required to be at least 30 years old or older, untreated with PD medications, diagnosed within the last two years, and to exhibit at least two or more PD-related motor symptoms, such as asymmetrical resting tremor, uneven bradykinesia, or a combination of bradykinesia, resting tremor, and rigidity³⁷. All individuals underwent dopamine transporter (DAT) imaging to confirm a DAT deficit as a prerequisite for eligibility³⁷. No significant effect of age, gender, or site was found³⁴.

For ALS, MRI data were collected from 66 patients (24 females; age 57.98 ± 10.84) with both sporadic or familial form of disease from centers of the Canadian ALS Neuroimaging Consortium (<http://calsnic.org/>, [ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02405182) NCT02405182), which included 3T MRI sites in University of Alberta, University of Calgary, University of Toronto, and McGill University^{33, 38}. Patients were included if they were diagnosed with sporadic or familial ALS, and meet the revised El Escorial research criteria¹⁰¹ for possible, laboratory supported, or definite ALS³⁸. Patients underwent a neurological exam administered by a trained neurologist at each participating site³⁸. All participants gave written informed consent, and the study was approved by the health research ethics boards at each of the participating sites³³. Participants were excluded if they had a history of other neurological or psychiatric disorders, prior brain injury or respiratory impairment resulting in an inability to tolerate the MRI protocol³³. Participants with primary lateral sclerosis, progressive muscular atrophy, or frontotemporal dementia were also excluded from the study³⁸. Normative aging as well as sex differences were regressed out from data prior the map construction³³.

For clinical subtypes of FTD, atrophy maps were obtained from the open-access database³⁵. These maps were derived from MRI data from the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI AG032306; part of the ALLFTD). As described in separate studies^{102, 103}, the data used for constructing these atrophy maps consisted of 136 patients diagnosed with frontotemporal dementia, alongside 133 age-matched control participants. Participants were previously stratified into groups according to their clinical variant of FTD: 70 patients were diagnosed with the behavioural variant, 36 with the semantic primary progressive aphasia, and 30 with the non-fluent primary progressive aphasia^{39, 102}. 3T structural images were collected on three following sites: University of California San Francisco, Mayo Clinic, and Massachusetts General Hospital³⁹. Patients were referred by physicians or self-referred, and all underwent neurological, neuropsychological, and functional assessment with informant interview³⁹. All individuals received their diagnoses during a multidisciplinary consensus conference using established criteria: Neary criteria¹⁰⁴ or, depending on year of enrolment, the recently published consensus criteria for bvFTD¹⁰⁵ and PPA¹⁰⁶. Histological analysis was conducted to assess whether patients might have Alzheimer's disease pathology since both conditions presents the overlap of clinical symptoms³⁹. All subjects provided informed consent and the protocol was approved by the institution review board at all sites³⁹.

Mapping gene expression data

To construct a comprehensive transcriptome atlas, we used RNA microarray gene expression data from the Allen Human Brain Atlas (AHBA; <https://human.brain-map.org/>)⁴³. The AHBA included anatomical and histological data collected from six healthy human specimens with no known neurological disease history (one female; age range 24–57 years; mean age 42.5 ± 13.38 years)⁴³. Two specimens contained data from the entire brain, whereas the remaining four included data from the left hemisphere only, with 3702 spatially distinct samples in total⁴³. The samples were distributed across cortical, subcortical, brainstem, and cerebellar regions in each brain, and the expression levels of more than 20,000 genes were quantified⁴³. mRNA data for specific brain locations were accompanied by structural MR data from each individual and were labeled with Talairach native coordinates¹⁰⁷ and Montreal Neurological Institute (MNI) coordinates⁴², which allowed us to match samples to imaging data.

Following the validated approach in ⁴⁴, missing data points between samples for each MNI coordinate were interpolated using Gaussian-process regression, a widely used method for data interpolation in geostatistics. The regression is performed as a weighted linear combination of missing mRNA, with the weights decreasing from proximal to distal regions. MNI coordinates for predicting mRNA values were taken from the GM regions of the AAL atlas. Spatial covariance between coordinates from the available 3072 AHBA tissue samples and coordinates from the AAL atlas was estimated via the quadratic exponential kernel function. mRNA expression at each MNI coordinate was then predicted by multiplying AHBA gene express values that corresponded to specific probes to kernel covariance matrix divided by the sum of kernels.

Cell-type proportion estimation

Densities for multiple canonical cell-types were estimated at the grey matter (GM) by applying an R-package Brain Cell-type Specific Gene Expression Analysis (BRETIGEA), with known genetic markers to the transcriptome atlas⁴⁵. This deconvolution method was designed for estimating cell proportions in bulk mRNA expression data for six major cell-types: neurons, astrocytes, oligodendrocytes, microglia, endothelial cells, and oligodendrocyte precursor cells^{45, 108}. We chose 15 representative gene markers per each cell-type (90 in total) from the BRETIGEA human brain marker gene set and then selected those genes that were also present in the AHBA gene expression database with matching gene probes. This resulted in eighty cell-type-related gene markers that were used in missing data interpolation and the deconvolution and proportion estimation analysis (**Table S3**). For each voxel, each cell-type proportion value was normalized relative to the sum of all six cell-types and the sum was scaled relative to the grey matter density. We then registered data into MNI and volumetric space using the ICBM152 template⁴².

For the correlation analysis, cell densities were averaged over 118 anatomical regions in grey matter defined by the extended automated anatomical labelling atlas (AAL; **Table S1**)⁴⁶. We repeated the correlation analysis for the 98 regions from the Desikan-Killiany-Tourville atlas (DKT; **Fig. S1**)⁴⁷.

Data analysis

We constructed a 6LJ×LJ11 correlation matrix by computing inter-regional Spearman's correlations between spatial distributions of the six canonical cell-types and patterns of atrophy in thirteen neurodegenerative conditions. All originally significant p-values ($p < 0.05$) from the correlation analysis survived correction for multiple comparisons using the false discovery rate (FDR)-controlling Benjamini-Hochberg method, with a significance threshold of 0.05. Shapiro-Wilk tests were used to examine the normality of data distribution. Hierarchical clustering analyses was applied using in-built MATLAB function for data visualization. Samples were clustered together based on estimated averaged linkage Euclidian distance between them.

Data and materials availability

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The BRETIGEA R package can be downloaded from <https://cran.r-project.org/package=BRETIGEA>. The Allen Human Brain Atlas data is available at <https://human.brain-map.org/static/download>. Atrophy maps for pathologically confirmed dementia are available at <http://neurovault.org/collections/ADHMHOPN/>. Raw demographic and MRI data from PD and ALS patients can be accessed at www.ppmiinfo.org/data and <http://calsnic.org/> (ClinicalTrials.gov NCT02405182), respectively. Atrophy maps for clinical variants of FTD are available at <https://zenodo.org/records/10383493>. Raw data from the FTL DNI initiative can be downloaded from the Laboratory of Neuroimaging (LONI) Image Data Archive at <https://ida.loni.usc.edu>. The cells abundance maps from this study are freely shared with the community and can be found at our lab's GitHub space <https://github.com/neuropm-lab/cellmaps>.

One Sentence Summary

Major cell-types distinctively associate with spatial vulnerability to tissue loss in thirteen neurodegenerative conditions.

Acknowledgements

This project was undertaken thanks in part to the following funding awards to YIM: the Canada Research Chair tier 2, the CIHR Project Grant 2020, the Weston Family Foundation's Transformational Research in AD 2020, and the New Investigator start-up grant from McGill University's *Healthy Brains for Healthy Lives Initiative* (HBHL, *Canada First Research Excellence Fund*). First author VP was supported by the Laszlo & Etelka Kollar Fellowship from the Faculty of Medicine and Health Sciences at McGill University and partly supported by the HBHL's Theme 1 Discovery fund 2022-2025. In addition, we used the computational infrastructure of the McConnell Brain Imaging Center at the Montreal Neurological Institute, supported in part by the *Brain Canada Foundation*, through the *Canada Brain Research Fund*, with the financial support of *Health Canada* and sponsors.

Competing interests

The authors declare no competing interest.




Figure S1.

Spatial associations between tissue integrity and cell-types proportions for thirteen neurodegenerative conditions in GM regions from the DKT parcellation (equivalent to main results from the AAL atlas in [Figure 2](#)).

#	Region name				
1	Precentral_L	41	Amygdala_L	81	Temporal_Sup_L
2	Precentral_R	42	Amygdala_R	82	Temporal_Sup_R
3	Frontal_Sup_L	43	Calcarine_L	83	Temporal_Pole_Sup_L
4	Frontal_Sup_R	44	Calcarine_R	84	Temporal_Pole_Sup_R
5	Frontal_Sup_Orb_L	45	Cuneus_L	85	Temporal_Mid_L
6	Frontal_Sup_Orb_R	46	Cuneus_R	86	Temporal_Mid_R
7	Frontal_Mid_L	47	Lingual_L	87	Temporal_Pole_Mid_L
8	Frontal_Mid_R	48	Lingual_R	88	Temporal_Pole_Mid_R
9	Frontal_Mid_Orb_L	49	Occipital_Sup_L	89	Temporal_Inf_L
10	Frontal_Mid_Orb_R	50	Occipital_Sup_R	90	Temporal_Inf_R
11	Frontal_Inf_Oper_L	51	Occipital_Mid_L	91	Cerebelum_Crus1_L
12	Frontal_Inf_Oper_R	52	Occipital_Mid_R	92	Cerebelum_Crus1_R
13	Frontal_Inf_Tri_L	53	Occipital_Inf_L	93	Cerebelum_Crus2_L
14	Frontal_Inf_Tri_R	54	Occipital_Inf_R	94	Cerebelum_Crus2_R
15	Frontal_Inf_Orb_L	55	Fusiform_L	95	Cerebelum_3_L
16	Frontal_Inf_Orb_R	56	Fusiform_R	96	Cerebelum_3_R
17	Rolandic_Oper_L	57	Postcentral_L	97	Cerebelum_4_5_L
18	Rolandic_Oper_R	58	Postcentral_R	98	Cerebelum_4_5_R
19	Supp_Motor_Area_L	59	Parietal_Sup_L	99	Cerebelum_6_L
20	Supp_Motor_Area_R	60	Parietal_Sup_R	100	Cerebelum_6_R
21	Olfactory_L	61	Parietal_Inf_L	101	Cerebelum_7b_L
22	Olfactory_R	62	Parietal_Inf_R	102	Cerebelum_7b_R
23	Frontal_Sup_Medial_L	63	SupraMarginal_L	103	Cerebelum_8_L
24	Frontal_Sup_Medial_R	64	SupraMarginal_R	104	Cerebelum_8_R
25	Frontal_Med_Orb_L	65	Angular_L	105	Cerebelum_9_L
26	Frontal_Med_Orb_R	66	Angular_R	106	Cerebelum_9_R
27	Rectus_L	67	Precuneus_L	107	Cerebelum_10_L
28	Rectus_R	68	Precuneus_R	108	Cerebelum_10_R
29	Insula_L	69	Paracentral_Lobule_L	109	Vermis_1_2
30	Insula_R	70	Paracentral_Lobule_R	110	Vermis_3
31	Cingulum_Ant_L	71	Caudate_L	111	Vermis_4_5
32	Cingulum_Ant_R	72	Caudate_R	112	Vermis_6
33	Cingulum_Mid_L	73	Putamen_L	113	Vermis_7
34	Cingulum_Mid_R	74	Putamen_R	114	Vermis_8
35	Cingulum_Post_L	75	Pallidum_L	115	Vermis_9
36	Cingulum_Post_R	76	Pallidum_R	116	Vermis_10
37	Hippocampus_L	77	Thalamus_L	117	Dentate_L
38	Hippocampus_R	78	Thalamus_R	118	Dentate_R
39	ParaHippocampal_L	79	Heschl_L		
40	ParaHippocampal_R	80	Heschl_R		

Table S1.

Cortical and subcortical regions from the AAL atlas.

Disease	Study	Year of publication	Journal / Database	Diseased participants (n)	Controls (n)	Method	Pathology confirmed
LOAD	Harper et al	2017	Neurol Neurosurg Psychiatry	68	73	VBM	yes
EOAD	Harper et al	2017	Neurol Neurosurg Psychiatry	29	73	VBM	yes
PS-1	Harper et al	2017	Neurol Neurosurg Psychiatry	10	73	VBM	yes
DLB	Harper et al	2017	Neurol Neurosurg Psychiatry	25	73	VBM	yes
FTLD-3RTau	Harper et al	2017	Neurol Neurosurg Psychiatry	11	73	VBM	yes
FTLD-4RTau	Harper et al	2017	Neurol Neurosurg Psychiatry	17	73	VBM	yes
FTLD-TDP43A	Harper et al	2017	Neurol Neurosurg Psychiatry	12	73	VBM	yes
FTLD-TDP43C	Harper et al	2017	Neurol Neurosurg Psychiatry	14	73	VBM	yes
PD	Zeighami et al	2015	eLife	232	117	DBM + ICA*	no
bvFTD	Dadar and Metz	2023	Zenodo	70	133	DBM	no
nfvPPA	Dadar and Metz	2023	Zenodo	36	133	DBM	no
svPPA	Dadar and Metz	2023	Zenodo	30	133	DBM	no
ALS	Dadar et al.	2020	Brain Communications	66	42	DBM	some

ICA* = tensor probabilistic independent component analysis

Table S2.

Origin of each disorder-associated t-statistic map.

Gene marker name	Cell-type
AQP4, BMPR1B, EDNRB, FGFR3, GFAP, GJA1, SDC4, SLC1A2, GJB6, ALDH1L1, SLC25A18	Astrocyte
C1QB, CD74, CXCR4, FOLR2, ITGAX, P2RX4, CCL3, CCL4, SLA, TLR1, TNFSF18, ARHGAP25, DHRS9, KBTBD8	Microglia
ANXA3, CD34, CFH, IFI27, TM4SF1, SELE, TGM2, VWF, SDPR, IFITM1, ITIH5, APOLD1, TM4SF18, GPR116	Endothelial cell
CHGB, CNR1, GABRA1, GABRB2, GAD2, KCNC2, OPRK1, RELN, SYT1, MYT1L, RIMBP2, ZMAT4, RAB3C, SYNPR, DLX6-AS1	Neuron
FOLH1, MAG, MOBP, CLDN11, PLP1, KLK6, CNTN2, TF, UGT8, ST18, ERMN, XYLT1, SH3TC2, CNDP1, TMEM64	Oligodendrocyte
GALR1, HAS2, NFYA, RGS13, TGFA, TNFR, FPGT, MMRN1, CDH19, CA10, CRISPLD1	Oligodendrocyte precursor cell

Table S3.

Eighty cell-type related gene markers provided by the BRETIGEA R package.

References

1. Gorman AM (2008) **Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling** *J Cell Mol Med* **12**:2263–2280
2. Duong S, Patel T, Chang F (2017) **Dementia: What pharmacists need to know** *Can Pharm J (Ott)* **150**:118–129
3. Bosco DA, LaVoie MJ, Petsko GA, Ringe D (2011) **Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis** *Cold Spring Harb Perspect Biol* **3**
4. Wingo TS, Liu Y, Gerasimov ES, et al. (2022) **Shared mechanisms across the major psychiatric and neurodegenerative diseases** *Nat Commun* **13**
5. Huseby CJ, Delvaux E, Brokaw DL, Coleman PD (2022) **Blood RNA transcripts reveal similar and differential alterations in fundamental cellular processes in Alzheimer's disease and other neurodegenerative diseases** *Alzheimers Dement*
6. Arneson D, Zhang Y, Yang X, Narayanan M (2018) **Shared mechanisms among neurodegenerative diseases: from genetic factors to gene networks** *J Genet* **97**:795–806
7. Zeighami Y, Bakken TE, Nickl-Jockschat T, et al. (2023) **A comparison of anatomic and cellular transcriptome structures across 40 human brain diseases** *PLoS Biol* **21**
8. Bordone MC, Barbosa-Morais NL (2020) **Unraveling Targetable Systemic and Cell-Type-Specific Molecular Phenotypes of Alzheimer's and Parkinson's Brains With Digital Cytometry** *Front Neurosci* **14**
9. Lee H, Fenster RJ, Pineda SS, et al. (2020) **Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation** *Neuron* **107**:891–908
10. Reynolds RH, Botia J, Nalls MA, et al. (2019) **Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability** *NPJ Parkinsons Dis* **5**
11. Wareham LK, Liddel SA, Temple S, et al. (2022) **Solving neurodegeneration: common mechanisms and strategies for new treatments** *Mol Neurodegener* **17**
12. Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N (2019) **Neuroinflammation as a Common Feature of Neurodegenerative Disorders** *Front Pharmacol* **10**
13. Kwon HS, Koh SH (2020) **Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes** *Transl Neurodegener* **9**
14. Kalaria RN (1999) **The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease** *Ann N Y Acad Sci* **893**:113–125
15. Chen X, Guo C, Kong J (2012) **Oxidative stress in neurodegenerative diseases** *Neural Regen Res* **7**:376–385

16. Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018) **Inflammation as a central mechanism in Alzheimer's disease** *Alzheimers Dement (N Y)* **4**:575–590
17. Leyns CEG, Holtzman DM (2017) **Glial contributions to neurodegeneration in tauopathies** *Mol Neurodegener* **12**
18. Maccioni RB, Rojo LE, Fernández JA, Kuljis RO (2009) **The role of neuroimmunomodulation in Alzheimer's disease** *Ann N Y Acad Sci* **1153**:240–246
19. Zang X, Chen S, Zhu J, Ma J, Zhai Y (2022) **The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases** *Front Aging Neurosci* **14**
20. Sochocka M, Donskow-Łysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J (2019) **The Gut Microbiome Alterations and Inflammation-Driven Pathogenesis of Alzheimer's Disease-a Critical Review** *Mol Neurobiol* **56**:1841–1851
21. Kempuraj D, Thangavel R, Natteru PA, et al. (2016) **Neuroinflammation Induces Neurodegeneration** *J Neurol Neurosurg Spine*
22. Castellani G, Croese T, Peralta Ramos JM, Schwartz M (2023) **Transforming the understanding of brain immunity** *Science* **380**
23. Vidal-Pineiro D, Parker N, Shin J, et al. (2020) **Cellular correlates of cortical thinning throughout the lifespan** *Sci Rep* **10**
24. Roshchupkin GV, Adams HH, van der Lee SJ, et al. (2016) **Fine-mapping the effects of Alzheimer's disease risk loci on brain morphology** *Neurobiol Aging* **48**:204–211
25. Zheng YQ, Zhang Y, Yau Y, et al. (2019) **Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation** *PLoS Biol* **17**
26. Altmann A, Cash DM, Bocchetta M, et al. (2020) **Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia** *Brain Commun*
27. Duran R Cuevas-Díaz, González-Orozco JC, Velasco I, Wu JQ (2022) **Single-cell and single-nuclei RNA sequencing as powerful tools to decipher cellular heterogeneity and dysregulation in neurodegenerative diseases** *Front Cell Dev Biol* **10**
28. Luquez T, Gaur P, Kosater IM, et al. (2022) **Cell type-specific changes identified by single-cell transcriptomics in Alzheimer's disease** *Genome Med* **14**
29. Riley BE, Gardai SJ, Emig-Agius D, et al. (2014) **Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms** *PLoS One* **9**
30. Arnatkeviciute A, Fulcher BD, Bellgrove MA, Fornito A (2022) **Imaging Transcriptomics of Brain Disorders** *Biol Psychiatry Glob Open Sci* **2**:319–331
31. Mrdjen D, Fox EJ, Bukhari SA, Montine KS, Bendall SC, Montine TJ (2019) **The basis of cellular and regional vulnerability in Alzheimer's disease** *Acta Neuropathol* **138**:729–749
32. Harper L, Bouwman F, Burton EJ, et al. (2017) **Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis** *J Neurol Neurosurg Psychiatry* **88**:908–916

33. Dadar M, Manera AL, Zinman L, et al. (2020) **Cerebral atrophy in amyotrophic lateral sclerosis parallels the pathological distribution of TDP43** *Brain Commun* **2**
34. Zeighami Y, Ulla M, Iturria-Medina Y, et al. (2015) **Network structure of brain atrophy in de novo Parkinson's disease** *Elife*
35. Dadar M, Metz A (2023) **Dadar M, Metz A. Atrophy Pattern Maps of Frontotemporal Dementia Variants (bvftd, Svppa, Pnfappa).** Zenodo 2023. <https://zenodo.org/records/10383493>
36. Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y, Rohrer JD (2022) **Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations** *Lancet Neurol* **21**:258–272
37. Parkinson Progression Marker I (2011) **The Parkinson Progression Marker Initiative (PPMI)** *Prog Neurobiol* **95**:629–635
38. Kalra S, Khan M, Barlow L, et al. (2020) **The Canadian ALS Neuroimaging Consortium (CALSNIC) - a multicentre platform for standardized imaging and clinical studies in ALS** *medRxiv*
39. Staffaroni AM, Ljubenkov PA, Kornak J, et al. (2019) **Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials** *Brain* **142**:443–459
40. Aubert-Broche B, Fonov VS, Garcia-Lorenzo D, et al. (2013) **A new method for structural volume analysis of longitudinal brain MRI data and its application in studying the growth trajectories of anatomical brain structures in childhood** *Neuroimage* **82**:393–402
41. Ashburner J, Friston KJ (2000) **Voxel-based morphometry--the methods** *Neuroimage* **11**:805–821
42. Fonov V, Evans AC, Botteron K, Almli CR, McKinstry RC, Collins DL (2011) **Unbiased average age-appropriate atlases for pediatric studies** *Neuroimage* **54**:313–327
43. Shen EH, Overly CC, Jones AR (2012) **The Allen Human Brain Atlas: comprehensive gene expression mapping of the human brain** *Trends Neurosci* **35**:711–714
44. Gryglewski G, Seiger R, James GM, et al. (2018) **Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging** *Neuroimage* **176**:259–267
45. McKenzie AT, Wang M, Hauberg ME, et al. (2018) **Brain Cell Type Specific Gene Expression and Co-expression Network Architectures** *Sci Rep* **8**
46. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. (2002) **Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain** *Neuroimage* **15**:273–289
47. Desikan RS, Ségonne F, Fischl B, et al. (2006) **An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest** *Neuroimage* **31**:968–980
48. Li J, Pan L, Pembroke WG, et al. (2021) **Conservation and divergence of vulnerability and responses to stressors between human and mouse astrocytes** *Nat Commun* **12**

49. González-Reyes RE, Nava-Mesa MO, Vargas-Sánchez K, Ariza-Salamanca D, Mora-Muñoz L (2017) **Involvement of Astrocytes in Alzheimer's Disease from a Neuroinflammatory and Oxidative Stress Perspective** *Front Mol Neurosci* **10**
50. Preininger MK, Kaufer D (2022) **Blood-Brain Barrier Dysfunction and Astrocyte Senescence as Reciprocal Drivers of Neuropathology in Aging** *Int J Mol Sci*
51. Yang P, Min X-L, Mohammadi M, et al. (2017) **Endothelial Degeneration of Parkinson's Disease is Related to Alpha-Synuclein Aggregation** *Journal of Alzheimer's Disease & Parkinsonism*
52. Salmina AB, Inzhutova AI, Malinovskaya NA, Petrova MM (2010) **Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: neuronal and glial control** *J Alzheimers Dis* **22**:17–36
53. Kalaria RN (1997) **Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer's disease** *Ann N Y Acad Sci* **826**:263–271
54. Procter TV, Williams A, Montagne A (2021) **Interplay between Brain Pericytes and Endothelial Cells in Dementia** *Am J Pathol* **191**:1917–1931
55. Geloso MC, Corvino V, Marchese E, Serrano A, Michetti F, D'Ambrosi N (2017) **The Dual Role of Microglia in ALS: Mechanisms and Therapeutic Approaches** *Front Aging Neurosci* **9**
56. Malpetti M, Jones PS, Hezemans FH, et al. (2022) **Microglial activation and atrophy in frontal cortex predict executive dysfunction in frontotemporal dementia** *Alzheimer's & Dementia*
57. Perea JR, Llorens-Martin M, Avila J, Bolos M (2018) **The Role of Microglia in the Spread of Tau: Relevance for Tauopathies** *Front Cell Neurosci* **12**
58. Keren-Shaul H, Spinrad A, Weiner A, et al. (2017) **A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease** *Cell* **169**:1276–1290
59. Vandenbark AA, Offner H, Matejuk S, Matejuk A (2021) **Microglia and astrocyte involvement in neurodegeneration and brain cancer** *J Neuroinflammation* **18**
60. Zhou Y, Song WM, Andhey PS, et al. (2020) **Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease** *Nat Med* **26**:131–142
61. Hu Y, Fryatt GL, Ghorbani M, et al. (2021) **Replicative senescence dictates the emergence of disease-associated microglia and contributes to Abeta pathology** *Cell Rep* **35**
62. Streit WJ, Khoshbouei H, Bechmann I (2020) **Dystrophic microglia in late-onset Alzheimer's disease** *Glia* **68**:845–854
63. Balusu S, Prashberger R, Lauwers E, De Strooper B, Verstreken P (2023) **Neurodegeneration cell per cell** *Neuron*
64. Lau V, Ramer L, Tremblay M (2023) **An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer's disease** *Nat Commun* **14**
65. Armada-Moreira A, Ribeiro FF, Sebastião AM, Xapelli S (2015) **Neuroinflammatory modulators of oligodendrogenesis** *Neuroimmunology and Neuroinflammation* **2**:263–273

66. Mot AI, Depp C, Nave KA (2018) **An emerging role of dysfunctional axon-oligodendrocyte coupling in neurodegenerative diseases** *Dialogues Clin Neurosci* **20**:283–292
67. Bryois J, Skene NG, Hansen TF, et al. (2020) **Genetic identification of cell types underlying brain complex traits yields insights into the etiology of Parkinson's disease** *Nat Genet* **52**:482–493
68. Feleke R, Reynolds RH, Smith AM, et al. (2021) **Cross-platform transcriptional profiling identifies common and distinct molecular pathologies in Lewy body diseases** *Acta Neuropathol* **142**:449–474
69. Agarwal D, Sandor C, Volpato V, et al. (2020) **A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders** *Nat Commun* **11**
70. Orimo S, Uchihara T, Kanazawa T, et al. (2011) **Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease** *Neuropathol Appl Neurobiol* **37**:791–802
71. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H (2000) **NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains** *Acta Neuropathol* **99**:14–20
72. Mathys H, Davila-Velderrain J, Peng Z, et al. (2019) **Single-cell transcriptomic analysis of Alzheimer's disease** *Nature* **570**:332–337
73. Ohtomo R, Iwata A, Arai K (2018) **Molecular Mechanisms of Oligodendrocyte Regeneration in White Matter-Related Diseases** *Int J Mol Sci*
74. Traiffort E, Morisset-Lopez S, Moussaed M, Zahaf A (2021) **Defective Oligodendroglial Lineage and Demyelination in Amyotrophic Lateral Sclerosis** *Int J Mol Sci*
75. Spaas J, van Veggel L, Schepers M, et al. (2021) **Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders** *Cell Mol Life Sci* **78**:4615–4637
76. Kelleher RJ, Shen J (2017) **Presenilin-1 mutations and Alzheimer's disease** *Proc Natl Acad Sci U S A* **114**:629–631
77. Kim WS, Kågedal K, Halliday GM (2014) **Alpha-synuclein biology in Lewy body diseases** *Alzheimers Res Ther* **6**
78. Ferrari R, Kapogiannis D, Huey ED, Momeni P (2011) **FTD and ALS: a tale of two diseases** *Curr Alzheimer Res* **8**:273–294
79. Perry DC, Miller BL (2013) **Frontotemporal dementia** *Semin Neurol* **33**:336–341
80. Iturria-Medina Y, Evans AC (2015) **On the central role of brain connectivity in neurodegenerative disease progression** *Front Aging Neurosci* **7**
81. Tremblay C, Rahayel S, Vo A, et al. (2021) **Brain atrophy progression in Parkinson's disease is shaped by connectivity and local vulnerability** *Brain Commun* **3**

82. Zeighami Y, Fereshtehnejad SM, Dadar M, et al. (2019) **A clinical-anatomical signature of Parkinson's disease identified with partial least squares and magnetic resonance imaging** *Neuroimage* **190**:69–78
83. Arnatkeviciute A, Fulcher BD, Fornito A (2019) **A practical guide to linking brain-wide gene expression and neuroimaging data** *Neuroimage* **189**:353–367
84. Jackson WS (2014) **Selective vulnerability to neurodegenerative disease: the curious case of Prion Protein** *Dis Model Mech* **7**:21–29
85. Lau SF, Cao H, Fu AKY, Ip NY (2020) **Single-nucleus transcriptome analysis reveals dysregulation of angiogenic endothelial cells and neuroprotective glia in Alzheimer's disease** *Proc Natl Acad Sci U S A* **117**:25800–25809
86. Johnson TS, Xiang S, Dong T, et al. (2021) **Combinatorial analyses reveal cellular composition changes have different impacts on transcriptomic changes of cell type specific genes in Alzheimer's Disease** *Sci Rep* **11**
87. Wang X, Allen M, Li S, et al. (2020) **Deciphering cellular transcriptional alterations in Alzheimer's disease brains** *Mol Neurodegener* **15**
88. Nido GS, Dick F, Toker L, et al. (2020) **Common gene expression signatures in Parkinson's disease are driven by changes in cell composition** *Acta Neuropathol Commun* **8**
89. Kerrebijn I, Wainberg M, Zhukovsky P, et al. (2023) **Case-control virtual histology elucidates cell types associated with cortical thickness differences in Alzheimer's disease** *Neuroimage* **276**
90. Liddel SA, Guttenplan KA, Clarke LE, et al. (2017) **Neurotoxic reactive astrocytes are induced by activated microglia** *Nature* **541**:481–487
91. Yun SP, Kam TI, Panicker N, et al. (2018) **Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease** *Nat Med* **24**:931–938
92. Fonov VS, Dadar M, Manera AL, Ducharme S, Collins L (2021) **Clinical subtypes of frontotemporal dementia show different patterns of cortical atrophy** *Alzheimer's & Dementia*
93. Rosenberg-Katz K, Herman T, Jacob Y, Giladi N, Hendler T, Hausdorff JM (2013) **Gray matter atrophy distinguishes between Parkinson disease motor subtypes** *Neurology* **80**:1476–1484
94. Dai R, Chu T, Zhang M, et al. (2023) **Evaluating performance and applications of sample-wise cell deconvolution methods on human brain transcriptomic data**
95. Iturria-Medina Y, Khan AF, Adewale Q, Shirazi AH (2020) **Alzheimer's Disease Neuroimaging I. Blood and brain gene expression trajectories mirror neuropathology and clinical deterioration in neurodegeneration** *Brain* **143**:661–673
96. Hammond TR, Dufort C, Dissing-Olesen L, et al. (2019) **Single-Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell-State Changes** *Immunity* **50**:253–271
97. Jaffe AE, Tao R, Norris AL, et al. (2017) **qSVA framework for RNA quality correction in differential expression analysis** *Proc Natl Acad Sci U S A* **114**:7130–7135

98. Yu X, Abbas-Aghababazadeh F, Chen YA, Fridley BL (2021) **Statistical and Bioinformatics Analysis of Data from Bulk and Single-Cell RNA Sequencing Experiments** *Methods Mol Biol* **2194**:143–175
99. Whitwell JL (2009) **Voxel-based morphometry: an automated technique for assessing structural changes in the brain** *J Neurosci* **29**:9661–9664
100. Chung MK, Worsley KJ, Paus T, et al. (2001) **A unified statistical approach to deformation-based morphometry** *Neuroimage* **14**:595–606
101. Brooks BR, Miller RG, Swash M, Munsat TL (2000) **El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis** *Amyotroph Lateral Scler Other Motor Neuron Disord* **1**:293–299
102. Dadar M, Manera AL, Fonov VS, Ducharme S, Collins DL (2021) **MNI-FTD templates, unbiased average templates of frontotemporal dementia variants** *Sci Data* **8**
103. Dadar M, Manera AL, Ducharme S, Collins DL (2022) **White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer’s disease and frontotemporal dementia** *Neurobiol Aging* **111**:54–63
104. Neary D, Snowden JS, Gustafson L, et al. (1998) **Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria** *Neurology* **51**:1546–1554
105. Rascovsky K, Hodges JR, Knopman D, et al. (2011) **Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia** *Brain* **134**:2456–2477
106. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. (2011) **Classification of primary progressive aphasia and its variants** *Neurology* **76**:1006–1014
107. Talairach J, Szikla G (1980) **Application of stereotactic concepts to the surgery of epilepsy** *Acta Neurochir Suppl (Wien)* **30**:35–54
108. Chikina M, Zaslavsky E, Sealfon SC (2015) **CellCODE: a robust latent variable approach to differential expression analysis for heterogeneous cell populations** *Bioinformatics* **31**:1584–1591

Article and author information

Veronika Pak

Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada, McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada, Ludmer Centre for Neuroinformatics & Mental Health, Montreal, Quebec, Canada

Quadri Adewale

Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada, McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada, Ludmer Centre for Neuroinformatics & Mental Health, Montreal, Quebec, Canada

ORCID iD: [0000-0001-5090-6140](https://orcid.org/0000-0001-5090-6140)

Danilo Bzdok

McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada, Department of Biomedical Engineering, McGill University, Montreal, Quebec, Canada, School of Computer Science, McGill University, Montreal, Quebec, Canada, Mila – Quebec Artificial Intelligence Institute, Montreal, Quebec, Canada
ORCID iD: [0000-0003-3466-6620](https://orcid.org/0000-0003-3466-6620)

Mahsa Dadar

The Douglas Research Center, Montreal, Quebec, Canada
ORCID iD: [0000-0003-4008-2672](https://orcid.org/0000-0003-4008-2672)

Yashar Zeighami

The Douglas Research Center, Montreal, Quebec, Canada
ORCID iD: [0000-0002-0583-5811](https://orcid.org/0000-0002-0583-5811)

Yasser Iturria-Medina

Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada, McConnell Brain Imaging Centre, Montreal Neurological Institute, Montreal, Quebec, Canada, Ludmer Centre for Neuroinformatics & Mental Health, Montreal, Quebec, Canada, McGill Centre for Studies in Aging, Montreal Quebec, Canada, Department of Biomedical Engineering, McGill University, Montreal, Quebec, Canada
For correspondence: yasser.iturriamedina@mcgill.ca
ORCID iD: [0000-0002-9345-0347](https://orcid.org/0000-0002-9345-0347)

Copyright

© 2023, Pak et al.

This article is distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.

Editors

Reviewing Editor

Alex Fornito

Monash University, Clayton, Australia

Senior Editor

Ma-Li Wong

State University of New York Upstate Medical University, Syracuse, United States of America

Reviewer #1 (Public Review):

This study explores the relationship between neurodegeneration's most common spatial patterns and the density of different cell types in the cerebral cortex. The authors present data showing that atrophy patterns in Alzheimer's disease and Frontotemporal dementia (FTD) strongly associated with the abundance of astrocytes and microglia. This work (the original manuscript and the revision) takes a step in the right direction by emphasizing the critical role that cells other than neurons play in the degeneration patterns observable with neuroimaging.

Comments on revised version:

I appreciate the revisions the authors made to address my main comments:

- adding whole-brain maps showing cellular abundance and atrophy
- stratifying the FTD group into the three clinically defined categories bvFTD (behavior-variant), nvPPA (nonfluent/agrammatic-variant primary progressive aphasia), and svPPA (semantic-variant primary progressive aphasia).

I reiterate my agreement with the authors that this work demonstrates the need to "surpass the current neuro-centric view of brain diseases and the imperative for identifying cell-specific therapeutic targets in neurodegeneration".

<https://doi.org/10.7554/eLife.89368.2.sa1>

Reviewer #3 (Public Review):

This study is a fine example of a recent productive trend in the integration of neuroimaging and molecular biology of the brain: in brief, overlaying some neuroimaging data (usually from a large cohort) onto the high spatial resolution gene expression in the Allen Human Brain Atlas data, derived from 6 individuals. By projecting structural MRI images over cell type proportions identified in the Allen data, the authors can represent various diseases in terms of their spatially-associated cell types. The result has implications for prioritizing the contributions of various cell types to each disease and creates an even-handed cell type profile through which the 11 diseases can be compared.

<https://doi.org/10.7554/eLife.89368.2.sa0>

Author Response

The following is the authors' response to the original reviews.

Reviewer 1: I would have preferred to see more figures with brain images showing the cellular abundance maps and the atrophy maps. Without being able to see these figures, it's difficult for the reader to 1) validate the atrophy patterns or 2) gain intuition about how the cellular abundance maps vary across the brain. The images in Figure 1C give a small preview, but I'd like to see these maps in their entirety on the brain surface or axial image slices.

(1) We added brain surface visualization plots of the voxel-wise cellular abundance maps to Figure 1 (lateral, dorsal, and ventral views of both hemispheres). To illustrate how their spatial distributions are associated with brain tissue damage, in Figure 2, we have also added brain surface visualizations of regional values from the atrophy t-statistic maps for the thirteen neurodegenerative conditions and the cell-type map most strongly associated with each condition. These plots allow us to observe variability across the cell-type density and atrophy maps, as well as to visually validate and compare how the patterns vary across the brain.

Reviewer 1: FTD is an umbrella category for a family of distinct clinical syndromes with different atrophy patterns. It doesn't seem a good idea to take the average of all subjects in this group to form a single atrophy map. Instead, different average maps for each syndrome should be provided.

(2) Considering the heterogeneity of clinical FTD syndromes, we addressed the reviewers' concerns about using the averaged atrophy map across all patients with an FTD diagnosis. As suggested, we accessed different atrophy maps for each major variant of clinical FTD,

including behavioral FTD ($n = 70$), as well as the semantic ($n = 36$) and nonfluent variants of primary progressive aphasia ($n = 30$). These maps are based on data from the participants from the same dataset of the Frontotemporal Lobar Degeneration Neuroimaging Initiative (FTLDNI) that we originally used. Similar to our previous results using the atrophy map averaged over all FTD patients, the analysis showed significant associations of atrophy patterns with cell type densities in all three major variants (see Figure 3A). Notably, these new findings offer insights into specific differences in spatial vulnerability of different cell-types across the variants of FTD, each characterized by unique symptoms, clinical manifestations, and atrophy patterns. In response to these additions, we have updated all figures, results, and interpretations accordingly.

Reviewer 2: In the abstract, the list of neurodegenerative disorders should be edited: frontotemporal dementia is an umbrella clinical syndrome, not a neurodegenerative disorder. Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disorder, and many tauopathies are FTLDs. While the authors grab their definitional classes from various sources (i.e., published cohort, and other studies), the reader fatigues to understand the population that is being assessed.

(3) To address potential confusion arising from the inclusion of atrophy maps from FTLD patients across two different studies, stratified based on both clinical and pathological criteria, we added clarifications regarding the assessed population and the used definitions. We used the term FTD when addressing the clinical syndromes, and the term FTLD was employed when referencing the histologically confirmed neurodegenerative pathologies. In addition, we added details on the diagnostic criteria employed for participant recruitment in the FTLDNI cohort, which data we used for atrophy maps in clinical subtypes of FTD. Lastly, throughout the text and within the figures, we systematically refined the nomenclature for FTLD pathological types, categorizing them based on their known definitions used in literature and type of proteinaceous inclusions (FTLD- 3-repeat and 4-repeat tauopathies and FTLD-TDP types A and C).

Reviewer 1: The results section contains perhaps too much interpretation. While the information that's provided serves as an interesting review (e.g., the discussion of the blood-brain barrier), the discussion may be a better place for this.

(4) We removed sentences with excessive interpretation but insisted on including those outlining the fundamental functions of cell types and their literature-based relevance to neurodegenerative diseases in the Results section, clarifying the significance of our findings to the readers.

Reviewer 2: The authors based their methodology on the use of a deconvolutional cell classifier; however, do not extensively recognize that their data on gene expression are based on normal brain levels rather than on diseased ones.

(5) We acknowledged that the gene expression data is based on normal human brain levels in figure titles and all sections of the paper (Introduction, Results, Discussion, Methods) to remind the readers that the analysis shows how changes in gray matter tissue in diseased brains correlates with healthy reference levels of cellular density.

Reviewer 2: More information in the text needs to be provided regarding the method used to infer gene expression levels at non-sampled brain locations. The reader should not be forced to read reference 40 or investigate the methods section. Figure 1 schematics do not sufficiently explain the used method.

(6) We added clarifications/references about the used Gaussian process regression for imputing gene expression (Results and figure titles).

Reviewer 2: Also, while predicted levels are uniquely based on patterns of brain atrophy, it is not possible to know whether this strategy is generalizable to all diseases (for instance, it is known that pure DLB, PD and ALS are not associated with extensive brain atrophy), or even adequately comparable between subtypes of diseases within the same class (e.g., different forms of FTLD). The authors do not acknowledge that only data based on true neuropathological assessment may prove whether their findings are true.

(7) Although diagnoses of most dementia conditions used in our study were histologically confirmed, we added acknowledgement about the importance of neuropathological assessment (Discussion section).